Swiss National Bank Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Swiss National Bank raised its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 1.2% during the fourth quarter, Holdings Channel reports. The firm owned 52,333 shares of the company’s stock after buying an additional 600 shares during the quarter. Swiss National Bank’s holdings in Tarsus Pharmaceuticals were worth $2,898,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TARS. Jennison Associates LLC grew its stake in shares of Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after buying an additional 321,552 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock valued at $63,499,000 after acquiring an additional 5,565 shares during the period. Ikarian Capital LLC grew its position in Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after acquiring an additional 230,000 shares in the last quarter. Geode Capital Management LLC increased its stake in Tarsus Pharmaceuticals by 8.1% during the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock worth $27,494,000 after purchasing an additional 62,555 shares during the period. Finally, Lord Abbett & CO. LLC lifted its position in shares of Tarsus Pharmaceuticals by 28.4% during the third quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company’s stock worth $19,565,000 after purchasing an additional 131,636 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $51.01 on Thursday. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm has a market capitalization of $1.96 billion, a PE ratio of -13.39 and a beta of 1.05. The business’s fifty day moving average price is $48.82 and its 200 day moving average price is $45.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TARS has been the subject of a number of research reports. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Guggenheim reissued a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $63.67.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,315 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the sale, the insider now directly owns 50,751 shares of the company’s stock, valued at $2,349,263.79. This represents a 4.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock worth $1,581,173 over the last three months. Insiders own 8.25% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.